Morgan Tourne

Dr. Morgan Tourne


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MCMarie Carbonnel
Marie Carbonnel
LLLaetitia Layoun
Laetitia Layoun
MPMarine Poulain
Marine Poulain
MTMorgan Tourne
Morgan Tourne
RMRouba Murtada
Rouba Murtada
Jean Marc AyoubiJean Marc Ayoubi
Jean Marc Ayoubi
Borderline ovarian tumors (BOT) represent about 10 to 20 percent of all epithelial tumors of the ovary. They constitute intermediate lesions between benign ovarian cysts and invasive carcinomas. They often occur in young women of reproductive age, and, albeit with a favorable prognosis, it may recur on the ipsilateral or contralateral ovary. Controversies surround the diagnostic criteria used for their assessment, and the optimal management to minimize their risk of recurrence and/or transformation into malignant carcinoma. Fertility preservation (FP) is considered a priority in the management of these patients, and studies aim at finding the safest and most effective way to help women with BOT history conceive with minimal risk. We present the experience of a single institution in managing three cases of serous BOT in young nulliparous women, followed by a thorough review of the existing literature, highlighting controversies and exploring the possible FP techniques for these women.

Verified
Journal Article
Open access
PDF file
MCMarie Carbonnel
Marie Carbonnel
CDCamille Daclin
Camille Daclin
MTMorgan Tourne
Morgan Tourne
EREmmanuel Roux
Emmanuel Roux
MLMathilde Le-Marchand
Mathilde Le-Marchand
JAJean-Marc Ayoubi
Jean-Marc Ayoubi
Background: In the context of the SARS-CoV-2 pandemic, our interest was to evaluate the effect of COVID-19 during pregnancy on placenta and coagulation factors. Methods: a prospective cohort study between January and July 2021 of 55 pregnant women stratified into: Group O, 16 patients with ongoing SARS-CoV-2 infection at delivery; Group R, 21 patients with a history of SARS-CoV-2 infection during pregnancy but who recovered prior to delivery; Group C, 18 control patients with no infection at any time. All women had nasopharyngeal SARS-CoV-2 RT-PCR tests performed within 72 h of delivery. Obstetrical complications were recorded and two physiological inhibitors of coagulation, protein Z (PZ) and dependent protease inhibitor (ZPI), were analyzed in maternal and cord blood. All placentae were analyzed by a pathologist for vascular malperfusion. Results: No patient in any group had a severe COVID-19 infection. More obstetrical complications were observed in Group O (O: n = 6/16 (37%), R: n = 2/21 (10%), C: n = 1/18 (6%), p = 0.03). The incidence of placental vascular malperfusion was similar among the groups (O: n = 9/16 (56%), R: n = 8/21 (42%), C: n = 8/18 (44%), p = 0.68). No PZ or ZPI deficiency was associated with COVID-19. However, an increased ZPI/PZ ratio was observed in neonates of Group R (O: 82.6 (min 41.3–max 743.6), R: 120.7 (29.8–203.5), C: 66.8 (28.2–2043.5), p = 0.04). Conclusion: COVID-19 was associated with more obstetrical complications, but not an increased incidence of placental lesions or PZ and ZPI abnormalities.

9 May 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MBMarc Bertaux
Marc Bertaux
CLCaroline Luo
Caroline Luo
CRCamelia Radulescu
Camelia Radulescu
PBPhilippe Beuzeboc
Philippe Beuzeboc
CLCécile Landais
Cécile Landais
SKSabrina Khedairia
Sabrina Khedairia
Background/Objectives: Immunotherapy is an essential part of metastatic bladder cancer treatment. Our main objective was to study the prognostic value of FDG-PET/CT in early assessment of response to Pembrolizumab in metastatic bladder cancers using PERCIST5, imPERCIST5, and PERCIMT criteria. Methods: A total of 42 patients were evaluated with FDG-PET/CT at baseline and after 3–4 cycles of Pembrolizumab. Treatment response was blindly assessed with PERCIST5, imPERCIST5, and PERCIMT. Imaging and clinical data were collected. Progression was defined clinically using oncologist reports. Results: A total of 37 patients were evaluable with the PERCIST5 and imPERCIST5 criteria and included in the analysis. Median disease-specific progression-free survival (PFS) and overall survival (OS) were 152 and 363 days, respectively. All response criteria were significantly associated with PFS. When response was dichotomized in responders versus non-responders all scores were significantly associated with OS. When response was dichotomized in progressors versus non-progressors, only PERCIST5 (hazard ratio (HR) 2.2) and PERCIMT (HR 2.6) were significantly associated with OS, while imPERCIST was not (HR 1.6). Two patients had pseudoprogression (5%), both being adequately classified as non-progressors with PERCIMT criteria. Conclusions: Early response to immunotherapy as assessed with FDG-PET is a strong prognostic factor in bladder cancer patients, especially using the PERCIST5 or PERCIMT criteria. The latter seems clinically useful as it is simple to perform and its specific definition of metabolic progression correctly ruled-out patients with significant clinical benefit of Pembrolizumab in our study.

27 October 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
CBClémence Basse
Clémence Basse
ALAlexandre Lanau
Alexandre Lanau
CKCamille Kergaravat
Camille Kergaravat
JMJeremy Mesple
Jeremy Mesple
ISInes Dias da Silva
Ines Dias da Silva
NGNicolas Girard
Nicolas Girard
Thymomas are rare thymic epithelial tumors harboring a high but variable proportion of lymphocytes without obvious function. Autoimmunity is present in one third of patients at diagnosis. In this study, we performed a phenotypic, single-cell RNA sequencing and spatial analysis of both the T cells and tumoral cells. T cells at all stages of T-cell development—from immature to mature—were present in the tumor, suggesting active thymopoiesis in thymoma. However, data generated through multiple approaches suggested a maturation blockade at the double-negative to double-positive stage of T-cell development. In the mature T-cell compartment, the frequency of regulatory T cells was strongly decreased. The single-cell RNA sequencing analysis showed that the transcriptome of tumoral thymic epithelial cells (TEC) was most similar to that of nontumoral medullary TEC, but the expression of key molecules involved in positive and negative selection was defective. Multiplexed IHC consecutive staining revealed a loss of the cortex–medulla zoning in thymoma, which may be related to a decrease in the expression of T cell–targeted chemokines by tumoral TEC. Altogether, these results suggest that the thymopoiesis present in thymoma is abnormal and may be the cause of the prevalent autoimmunity observed in this disease.

8 January 2026
Verified
Other
Open access
PDF file
CBClémence Basse
Clémence Basse
ALAlexandre Lanau
Alexandre Lanau
CKCamille Kergaravat
Camille Kergaravat
JMJeremy Mesple
Jeremy Mesple
ISInes Dias da Silva
Ines Dias da Silva
NGNicolas Girard
Nicolas Girard
Sup. Fig. S6. Current trajectory predictions from early immature DN populations towards DP and SP mature T cells are not driven by spliceosome dynamic modification

8 January 2026
Verified
Other
Open access
PDF file
CBClémence Basse
Clémence Basse
ALAlexandre Lanau
Alexandre Lanau
CKCamille Kergaravat
Camille Kergaravat
JMJeremy Mesple
Jeremy Mesple
ISInes Dias da Silva
Ines Dias da Silva
NGNicolas Girard
Nicolas Girard
Sup. Fig. S4. Treg abundance alteration, and maintenance of IL2 production by the CD4 cells in the tumor samples.